{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:17:42Z","timestamp":1747196262741,"version":"3.40.5"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12\/1\/2020 and 11\/30\/2021. The primary endpoint was a positive anti-COVID spike protein antibody level following the primary COVID vaccination series. The primary vaccination series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher\u2019s exact test, and unadjusted and adjusted logistic regression models were used for univariate and multivariate analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt\u2019s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL); 44 patients (18%) with Hodgkin and T-cell lymphomas (HL\/TCL) combined; 12 patients (5%) with mantle cell lymphoma; and 4 patients (2%) with other lymphoma types. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL\/SLL had a numerically lower seroconversion rate of 51% following the primary vaccination series whereas patients with HL\/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p = 0.04). Lymphoma patients are capable of mounting a humoral response to the COVID vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population.<\/jats:p>","DOI":"10.1371\/journal.pone.0266584","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T20:03:10Z","timestamp":1669924990000},"page":"e0266584","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-spike antibody response to the COVID vaccine in lymphoma patients"],"prefix":"10.1371","volume":"17","author":[{"given":"Alexandra","family":"Della Pia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-3017","authenticated-orcid":true,"given":"Gee Youn (Geeny)","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5618","authenticated-orcid":true,"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeil","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3525","authenticated-orcid":true,"given":"Simone","family":"Kats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6922-9370","authenticated-orcid":true,"given":"Michael","family":"Koropsak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Lukasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamta","family":"Contractor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krushna","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-2220","authenticated-orcid":true,"given":"Charles","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amolika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Batistick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-6522","authenticated-orcid":true,"given":"Andre H.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"issue":"25","key":"pone.0266584.ref001","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"A. Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"10","key":"pone.0266584.ref002","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"ITA-HEMA-COV Investigators","year":"2020","journal-title":"The Lancet. Haematology"},{"issue":"3","key":"pone.0266584.ref003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"F Passamonti","year":"2021","journal-title":"Br J Haematol"},{"issue":"18","key":"pone.0266584.ref004","doi-asserted-by":"crossref","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged \u226565 Years\u2014United States, January-March 2021","volume":"70","author":"MW Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"pone.0266584.ref005","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1093\/cid\/ciab397","article-title":"Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019","volume":"73","author":"G Haidar","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pone.0266584.ref006","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T Cell Dysfunction in Cancer Immunity and Immunotherapy","volume":"10","author":"A Xia","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"pone.0266584.ref007","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"LM Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"9","key":"pone.0266584.ref008","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"P Ghione","year":"2021","journal-title":"Blood"},{"issue":"2","key":"pone.0266584.ref009","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41375-021-01418-8","article-title":"Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin\u2019s lymphomas","volume":"36","author":"F Marchesi","year":"2022","journal-title":"Leukemia"},{"issue":"23","key":"pone.0266584.ref010","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Y Herishanu","year":"2021","journal-title":"Blood"},{"issue":"3","key":"pone.0266584.ref011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"O Benjamini","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"pone.0266584.ref012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"H Parry","year":"2021","journal-title":"Blood cancer journal"},{"issue":"9","key":"pone.0266584.ref013","first-page":"2703","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"LE Roeker","year":"2021"},{"issue":"10","key":"pone.0266584.ref014","first-page":"1297","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"LM Greenberger","year":"2021"},{"issue":"8","key":"pone.0266584.ref015","first-page":"1034","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"S Ehmsen","year":"2021"},{"issue":"3","key":"pone.0266584.ref016","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"A Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"issue":"12","key":"pone.0266584.ref017","doi-asserted-by":"crossref","first-page":"e93222","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"A Cho","year":"2017","journal-title":"JCI Insight"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T20:03:20Z","timestamp":1669925000000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266584"}},"subtitle":[],"editor":[{"given":"Victor C.","family":"Huber","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266584","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}